The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prevalence and impact of diabetes among people infected with SARS-CoV-2
Open accessAbstract
In December 2019, a new coronavirus causing severe acute respiratory syndrome (SARS-CoV-2) emerged in Wuhan, China. The virus spread rapidly to more than 150 countries and, by the time we are writing (March 19th 2020), it affected > 230,000 individuals causing almost 10,000 deaths [1]. It has been suggested that diabetes mellitus is one of the most common comorbidities in infected people, but its exact prevalence is unclear. We show results of a meta-analysis of studies reporting the prevalence of diabetes among people infected with the SARS-CoV-2 and its impact on disease severity or progression. We retrieved 12 studies reporting data from 2108 Chinese patients with confirmed SARSCov-2 infection (Data supplement). Mean age was 49.6 years and the prevalence of diabetes was 10.3% (Fig. 1a). For comparison, the nationwide prevalence of diabetes in China in 2013 was 10.9% overall and 12.3% among people aged 40–59 [2]. As of March 19th 2020, Italy was the second country most affected with SARS-Cov-2 (n = 41,035 individuals with confirmed SARS-CoV-2). At the University Hospital of Padova, located at the centre of an outbreak, among 146 hospitalized patients with confirmed SARS-CoV-2 infection and a mean age of 65.3 years, 13 had pre-existing diabetes, yielding a prevalence of 8.9% (95% CI 5.3–14.6). For comparison, the prevalence of diabetes in the same Region in 2018 was 6.2% overall and 11.0% among people aged 55–75 years (mean 65) [3]. A relatively low prevalence of diabetes among SARS-CoV-2 infected people could be due to under-reporting, chance, or a biological phenomenon. Dipeptidyl peptidase-4 (DPP-4) was discovered as a receptor for middle-east respiratory syndrome coronavirus while SARS-CoV-2 appears to use preferentially angiotensin-converting enzyme 2 to enter the cell [4]. However, since DPP-4 inhibitors are popular glucose-lowering medications worldwide, it will be of interest to explore whether they might protect against SARS-CoV-2 infection. Six of the meta-analysed studies on Chinese patients reported the prevalence of diabetes according to disease severity or outcome (n = 1687 patients). The pooled rate ratio of diabetes among patients with adverse disease course as compared to those with the more favourable course was 2.26 (95% CI 1.47–3.49) (Fig. 1b and Supplemental Table 1). As of March 17th, the median age of 2003 Italian patients who died while being infected with SARS-CoV-2 was 80.5 (IQR 31–103) and 70% were men. Among 355 deceased patients with available information on comorbidities, diabetes prevalence was 35.5% [5]. In 2018, diabetes prevalence among Italian citizens with the same age range and sex distribution was 20.3% [6]. Thus, the rate ratio of diabetes among patients who died with SARS-CoV-2 infection compared to the general population was 1.75. Based on these data, we conclude that diabetes may not increase the risk of SARS-CoV-2 infection but can worsen the outcome of this new coronavirus disease. This finding is consistent with the association between diabetes and excess mortality from any acute and chronic condition, including infections [7]. The situation is rapidly evolving, and close monitoring of these data are important for a correct communication to patients and healthcare providers. Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s4061 8-020-01236 -2) contains supplementary material, which is available to authorized users.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · cited 1×
“Dipeptidyl peptidase-4 (DPP-4) was discovered as a receptor for middle-east respiratory syndrome coronavirus while SARS-CoV-2 appears to use preferentially angiotensin-converting enzyme 2 to enter the cell [4] .”
BackgroundPrevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., Li, Y., Zhao, Z., Qin, X., Jin, D., et al. (2017) · JAMA · doi:10.1001/jama.2017.7596 · Cited by 1,844
Mortality from infectious diseases in diabetes
Zoppini, G., Fedeli, U., Schievano, E., Dauriz, M., Targher, G., Bonora, E., & Corti, M. C. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.12.007 · Cited by 73
Longato, E., Camillo, B. D., Sparacino, G., Saccavini, C., Avogaro, A., & Fadini, G. P. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.08.017 · Cited by 49
Self-citation
Cited by
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30238-2 · Cited by 903
Dessie, Z. G., & Zewotir, T. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06536-3 · Cited by 875
COVID-19 and diabetes: Knowledge in progress
Hussain, A., Bhowmik, B., & do Vale Moreira, N. C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108142 · Cited by 796
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.044 · Cited by 776
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Metadata
- Authors
- Fadini, G. P., Morieri, M. L., Longato, E., & Avogaro, A.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2020-03-28
- Volume
- 43
- Issue
- 6
- Pages
- 867-869
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W3013365852
- Cited by
- 549
- References
- 4
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.